AbbVie: The Immortal Dividend Alchemist

Oh, but do not be deceived! For every Humira – a drug so profitable it could make Midas blush – there lurks a cliff so steep it would make Icarus reconsider his flight path. When the curtain fell on Humira’s exclusivity in 2023, the chorus of doom cried out. Yet AbbVie, with the flair of a magician pulling rabbits from hats, summoned forth Skyrizi and Rinvoq – phoenixes rising from the ashes of regulatory filings.





